LAX.SH
THYROCARE TECH LTD·DIAGNOSTICS 65.90·Healthcare Services Companies
Price
472.1
+3.48%52W Range
Market Cap
₹7,514.19 Cr
Traded: ₹21.30 Cr (0.28%) 0.0x
Free Float: ₹955.05 Cr (2.23% of FF traded)
Volume · 60D trend
4.55 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
RS Score
Create a free account to unlock your edge
Scanners, market pulse, FII/DII data, and TradingView charts — free forever
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | +13.0% | +11.0% | +16.0% | -- | +21.0% | Accelerating |
| ROE | +21.0% | +20.0% | +20.0% | -- | -- | Stable |
| Return | +11.0% | +5.0% | +41.0% | +36.0% | -- | Stable |
| Profit | +12.0% | +8.0% | +36.0% | -- | +70.0% | Accelerating |
Quarterly Results
Mar 2023
Dec 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 240 | 224 | 196 | 217 | 193 | 187 | 166 | 177 | 157 | 154 | 135 | 148 | 135 | 136 | 128 |
| Expenses | 163 | 149 | 138 | 145 | 135 | 130 | 124 | 129 | 115 | 121 | 103 | 110 | 100 | 111 | 100 |
| Operating Profit | 77 | 75 | 58 | 71 | 58 | 57 | 42 | 48 | 42 | 34 | 32 | 38 | 35 | 25 | 28 |
| Other Income | 5 | 5 | -1 | 3 | 5 | 5 | 4 | 3 | 4 | 3 | 3 | 3 | 1 | 4 | 3 |
| Interest | 1 | 2 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 12 | 14 | 22 | 12 | 11 | 14 | 17 | 13 | 11 | 13 | 13 | 11 | 10 | 11 | 10 |
| Profit Before Tax | 68 | 64 | 35 | 63 | 50 | 47 | 28 | 37 | 34 | 23 | 20 | 28 | 25 | 17 | 20 |
| Tax % | 25.0% | 24.0% | 21.0% | 24.0% | 24.0% | 54.0% | 32.0% | 28.0% | 29.0% | 25.0% | 26.0% | 28.0% | 31.0% | 28.0% | 25.0% |
| Net Profit | 51 | 49 | 28 | 48 | 38 | 22 | 19 | 26 | 24 | 17 | 15 | 20 | 17 | 12 | 15 |
| Exceptional Items | -- | 0 | -6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Rs) | 3.3 | 3.0 | 1.8 | 3.0 | 2.5 | 1.4 | 1.2 | 1.7 | 1.5 | 1.1 | 1.0 | 1.3 | 1.1 | 0.8 | 0.9 |
| Sales Growth (YoY) | -- | 19.7% | 17.9% | 22.1% | 23.0% | 21.3% | 23.1% | 19.8% | 16.3% | 13.5% | 5.2% | 9.7% | 5.6% | 4.1% | -- |
| Sales Growth (QoQ) | -- | 14.3% | -9.7% | 12.4% | 3.2% | 12.7% | -6.2% | 12.7% | 1.9% | 14.1% | -8.8% | 9.6% | -0.7% | 6.3% | -- |
| OP Growth (YoY) | 32.8% | 31.6% | 38.1% | 47.9% | 38.1% | 67.6% | 31.3% | 26.3% | 20.0% | 36.0% | 14.3% | -- | -- | -- | -- |
| OP Growth (QoQ) | 2.7% | 29.3% | -18.3% | 22.4% | 1.8% | 35.7% | -12.5% | 14.3% | 23.5% | 6.3% | -15.8% | 8.6% | 40.0% | -10.7% | -- |
| Profit Growth (YoY) | 34.0% | 117.0% | 75.0% | 80.0% | 61.0% | 22.0% | 24.0% | 31.0% | 40.0% | 41.0% | 4.0% | 32.0% | -20.0% | -41.0% | -32.0% |
| EPS Growth (YoY) | -- | 117.7% | 51.7% | 79.8% | 61.2% | 21.4% | 23.7% | 31.3% | 39.5% | 41.8% | 4.3% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | 62.6% | -39.7% | 23.3% | 80.2% | 13.3% | -28.6% | 10.5% | 35.7% | 15.5% | -24.2% | 17.4% | 38.0% | -15.1% | -- |
| OP Margin | -- | 33.5% | 29.6% | 32.7% | 30.1% | 30.5% | 25.3% | 27.1% | 26.8% | 22.1% | 23.7% | 25.7% | 25.9% | 18.4% | 21.9% |
| Net Margin | -- | 21.9% | 14.3% | 22.1% | 19.7% | 11.8% | 11.4% | 14.7% | 15.3% | 11.0% | 11.1% | 13.5% | 12.6% | 8.8% | 11.7% |
| Material Cost % | -- | 25.3% | 24.1% | 27.7% | 28.8% | 26.4% | 27.2% | 28.8% | 29.0% | 30.2% | 28.5% | 29.5% | 28.2% | 30.7% | 31.9% |
| Employee Cost % | -- | 16.1% | 18.3% | 15.3% | 17.1% | 17.9% | 21.1% | 16.6% | 18.3% | 17.2% | 19.6% | 18.3% | 20.7% | 20.8% | 21.1% |
| P/S | 8.58 | 10.46 | 9.45 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 42.61 | 53.20 | 54.42 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 12.84 | 14.84 | 14.03 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Thyrocare Technologies Limited cordially invites you to its "Q2 FY2026-27 Earnings Call" to be held on Thursday, October 29, 2026 at 06.00 P.M. to discuss the financial performance of the ....
Thyrocare Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2026 ,inter alia, to consider and approve the Unaudited Standalone ....
Please find attached herewith Certificate pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026
Please find attached the Copies of Newspaper Publications for Notice of Postal Ballot
Please find attached intimation regarding Acquisition of Compulsorily Convertible Preference Shares of Trovera Healthcare Private Limited as part-consideration for the sale of Nueclear ....
Please find attached Intimation Letter
Outcome of the Board meeting held on Monday, September 21, 2026
The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 08, 2026 for Docon Technologies ....
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for API Holdings Ltd
Please find enclosed herewith copies of Newspaper Publications published on September 04, 2026 in Business Standard (English) and Lakshadeep (Marathi)
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for API Holdings Ltd
Please find enclosed the Intimation regarding approval of Scheme of Amalgamation of Docon Technologies Private Limited with API Holdings Limited
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Docon Technologies Pvt Ltd & PACs
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Docon Technologies Pvt Ltd
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for HSBC Mutual Fund
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 13, 2026 for Docon Technologies Pvt Ltd
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Docon Technologies Pvt Ltd & PAC
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 17, 2026 for Docon Technologies Pvt Ltd
Please refer the enclosed intimation letter
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for ICICI Prudential Mutual Fund
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Docon Technologies Pvt Ltd
Please refer the enclosed intimation letter.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Docon Technologies Pvt Ltd & PACs
Please find the attached disclosure received from Docon Technologies Private Limited ("Promoter") for release of pledge on equity shares of the Company
Please find attached the Earnings Call Transcript held on July 23, 2026
Please find attached herewith Newspaper Publication of Unaudited Financial Results for the quarter ended on June 30, 2026
Thyrocare Technologies Limited has informed the exchange regarding submission of machine-readable document of earlier submitted results of the Company for the quarter ended on June 30, 2026
Please find enclosed the unaudited standalone and consolidated financial results of the Company for the quarter ended on June 30, 2026
Please find attached the Press Release on the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended on June 30, 2026
Please find attached the Investor Presentation on the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended on June 30, 2026
Please find attached the Intimation regarding the re-appointment of the Internal Auditor of the Company.
Please refer the enclosed intimation regarding the in-principle approval of the Board of Directors of the Company for evaluation of the proposed restructuring of the radiology business ....
Audio Recording of Earnings Conference Call for the quarter ended on June 30, 2026
Please find enclosed outcome of the Board Meeting held on July 23, 2026, inter alia, approving the unaudited financial results for the quarter ended June 30, 2026, as detailed in the enclosed letter.
Thyrocare Technologies Limited cordially invites you to its "Earning Call" to be held on Thursday, July 23, 2026 at 06.00 P.M. to discuss the financial performance of the company for Q1 FY27.
Thyrocare Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/07/2026 ,inter alia, to consider and approve Unaudited Standalone ....
Please find attached herewith Certificate pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2026
Please find enclosed intimation regarding Amendments to Memorandum of Association of the Company.
Please find enclosed intimation regarding change in Statutory Auditors of the Company
Proceedings of the 26th Annual General Meeting held on 30th June, 2026. Further the scrutinizer''s report along with voting results is enclosed.
Please find attached the Intimation for Closure of Trading Window
Please find enclosed communication sent to shareholders for deduction of tax on dividend.
Please find attached the Annual Report of Thyrocare Technologies Limited for the FY 2025-26.
Please find attached the Business Responsibility and Sustainability Reporting (BRSR) of the Company for the FY 2025-26
Please find attached intimation of Record Date for the purpose of final dividend for the FY 2025-26.
Please find attached the Notice of 26th Annual General Meeting along with Annual Report for the FY 2025-26.
Please find enclosed herewith copies of Newspaper Publications published on May 25, 2026 in Business Standard (English) and Pratahkal (Marathi)
Please find attached the Earnings Call Transcript held on May 12, 2026
Annual Reports
11Concalls
35Feb 2026
28 Feb 2026Oct 2025
31 Oct 2025Jul 2025
31 Jul 2025Apr 2025
30 Apr 2025Jan 2025
31 Jan 2025Oct 2024
31 Oct 2024Jul 2024
31 Jul 2024May 2024
31 May 2024Feb 2024
29 Feb 2024Nov 2023
30 Nov 2023Aug 2023
31 Aug 2023May 2023
31 May 2023Feb 2023
28 Feb 2023Nov 2022
30 Nov 2022Aug 2022
31 Aug 2022May 2022
31 May 2022Feb 2022
28 Feb 2022Nov 2021
30 Nov 2021Aug 2021
31 Aug 2021May 2021
31 May 2021Feb 2021
28 Feb 2021Nov 2020
30 Nov 2020Jul 2020
31 Jul 2020May 2020
31 May 2020Feb 2020
29 Feb 2020Nov 2019
30 Nov 2019Aug 2019
31 Aug 2019Jun 2019
30 Jun 2019May 2019
31 May 2019Feb 2019
28 Feb 2019Nov 2018
30 Nov 2018Aug 2018
31 Aug 2018May 2018
31 May 2018Feb 2018
28 Feb 2018Dec 2017
31 Dec 2017Held by ETFs
2 ETFs hold THYROCARE · sorted by weight
Held by Mutual Funds
24 schemes hold THYROCARE · sorted by weight